These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Lipoprotein glomerulopathy with markedly increased arterial stiffness successfully treated with a combination of fenofibrate and losartan: a case report. Kato J; Okonogi H; Kanzaki G; Katsumata H; Nakada Y; Sagasaki M; Komine K; Ito K; Saito T; Matsunaga A; Tokutou K; Honda K; Tsuboi N; Yokoo T BMC Nephrol; 2024 May; 25(1):171. PubMed ID: 38769490 [TBL] [Abstract][Full Text] [Related]
3. Lipoprotein glomerulopathy associated with the Osaka/Kurashiki APOE variant: two cases identified in Latin America. da Silveira-Neto JN; de Oliveira Ahn GJ; de Menezes Neves PDM; Baptista VAF; de Almeida Araújo S; Wanderley DC; Watanabe A; Watanabe EH; Murai NM; Bertollo EMG; Vieira-Neto OM; Dantas M; de Antônio SR; Costa RS; Baptista MASF; Moysés-Neto M; Onuchic LF Diagn Pathol; 2021 Jul; 16(1):65. PubMed ID: 34311745 [TBL] [Abstract][Full Text] [Related]
4. Lipoprotein glomerulopathy: a new apolipoprotein E mutation with enhanced glomerular binding. Sam R; Wu H; Yue L; Mazzone T; Schwartz MM; Arruda JA; Dunea G; Singh AK Am J Kidney Dis; 2006 Mar; 47(3):539-48. PubMed ID: 16490634 [TBL] [Abstract][Full Text] [Related]
5. A novel apolipoprotein E mutation, ApoE Ganzhou (Arg43Cys), in a Chinese son and his father with lipoprotein glomerulopathy: two case reports. Wang R; Zhao C; Chen W; Liu Z; Xie F J Med Case Rep; 2022 Feb; 16(1):78. PubMed ID: 35193676 [TBL] [Abstract][Full Text] [Related]
6. Lipoprotein glomerulopathy induced by ApoE-Sendai is different from glomerular lesions in aged apoE-deficient mice. Ishimura A; Watanabe M; Nakashima H; Ito K; Miyake K; Mochizuki S; Ishigaki Y; Saito T Clin Exp Nephrol; 2009 Oct; 13(5):430-437. PubMed ID: 19459027 [TBL] [Abstract][Full Text] [Related]
7. Lipoprotein glomerulopathy induced by ApoE Kyoto mutation in ApoE-deficient mice. Wu H; Yang J; Liu YQ; Lei S; Yang M; Yang Z; Yang Y; Hu Z J Transl Med; 2021 Mar; 19(1):97. PubMed ID: 33663537 [TBL] [Abstract][Full Text] [Related]
8. Lipoprotein glomerulopathy resulting from compound heterogeneous mutations of APOE gene: A case report. Li Y; Chen J; Zou Y; Wang W; Li G Medicine (Baltimore); 2022 Feb; 101(5):e28718. PubMed ID: 35119017 [TBL] [Abstract][Full Text] [Related]
9. Diminished LDL receptor and high heparin binding of apolipoprotein E2 Sendai associated with lipoprotein glomerulopathy. Hoffmann MM; Scharnagl H; Panagiotou E; Banghard WT; Wieland H; März W J Am Soc Nephrol; 2001 Mar; 12(3):524-530. PubMed ID: 11181800 [TBL] [Abstract][Full Text] [Related]
10. [Clinicopathologic features of lipoprotein glomerulopathy: observation of 6 cases]. Zou GM; Zhuo L; Tan M; Li WG Zhonghua Yi Xue Za Zhi; 2018 Sep; 98(36):2910-2913. PubMed ID: 30293348 [No Abstract] [Full Text] [Related]
11. Plasma level and genetic variation of apolipoprotein E in patients with lipoprotein glomerulopathy. Zhang B; Liu ZH; Zeng CH; Zheng JM; Chen HP; Zhou H; Li LS Chin Med J (Engl); 2005 Apr; 118(7):555-60. PubMed ID: 15820086 [TBL] [Abstract][Full Text] [Related]
12. A new apolipoprotein E mutation, apoE Las Vegas, in a European-American with lipoprotein glomerulopathy. Bomback AS; Song H; D'Agati VD; Cohen SD; Neal A; Appel GB; Rovin BH Nephrol Dial Transplant; 2010 Oct; 25(10):3442-6. PubMed ID: 20624773 [TBL] [Abstract][Full Text] [Related]
13. Lipoprotein glomerulopathy: significance of lipoprotein and ultrastructural features. Saito T; Oikawa S; Sato H; Sato T; Ito S; Sasaki J Kidney Int Suppl; 1999 Jul; 71():S37-41. PubMed ID: 10412734 [TBL] [Abstract][Full Text] [Related]
15. A novel apolipoprotein E mutation, ApoE Osaka (Arg158 Pro), in a dyslipidemic patient with lipoprotein glomerulopathy. Mitani A; Ishigami M; Watase K; Minakata T; Yamamura T J Atheroscler Thromb; 2011; 18(6):531-5. PubMed ID: 21325775 [TBL] [Abstract][Full Text] [Related]
16. A case of apolipoprotein E Toyonaka and homozygous apolipoprotein E2/2 showing non-immune membranous nephropathy-like glomerular lesions with foamy changes. Kato T; Ushiogi Y; Yokoyama H; Hara S; Matsunaga A; Muso E; Saito T CEN Case Rep; 2019 May; 8(2):106-111. PubMed ID: 30701487 [TBL] [Abstract][Full Text] [Related]
17. Apolipoprotein E-related glomerular disorders. Saito T; Matsunaga A; Fukunaga M; Nagahama K; Hara S; Muso E Kidney Int; 2020 Feb; 97(2):279-288. PubMed ID: 31874799 [TBL] [Abstract][Full Text] [Related]
18. A novel apolipoprotein E mutation caused by a five amino acid deletion in a Chinese family with lipoprotein glomerulopathy: a case report. Xie W; Xie Y; Lin Z; Xu X; Zhang Y Diagn Pathol; 2019 May; 14(1):41. PubMed ID: 31092271 [TBL] [Abstract][Full Text] [Related]
19. A rare case of lipoprotein glomerulopathy in a white man: an emerging entity in Asia, rare in the white population. Boumendjel R; Papari M; Gonzalez M Arch Pathol Lab Med; 2010 Feb; 134(2):279-82. PubMed ID: 20121619 [TBL] [Abstract][Full Text] [Related]
20. Lipoprotein glomerulopathy associated with psoriasis vulgaris: report of 2 cases with apolipoprotein E3/3. Chang CF; Lin CC; Chen JY; Yang AH; Shiao MS; Kao JT; Yang WC Am J Kidney Dis; 2003 Sep; 42(3):E18-23. PubMed ID: 12955707 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]